Valuation: Shield Therapeutics plc

Market Cap 58.31M 77.7M 69.62M 64.33M 109M 7.39B 110M 769M 306M 3.87B 291M 285M 12.26B P/E 2026 *
363x
P/E 2027 * 7.35x
Enterprise Value 76.76M 102M 91.65M 84.68M 143M 9.73B 145M 1.01B 403M 5.09B 383M 376M 16.14B EV / Sales 2026 *
1.44x
EV / Sales 2027 * 1.09x
Free-Float
38.49%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Shield Therapeutics plc

1 week-1.80%
Current month-9.47%
1 month+4.81%
3 months-4.39%
6 months-38.42%
Current year-44.67%
1 week 5.3
Extreme 5.3
5.8
1 month 4.95
Extreme 4.95
6.1
Current year 3.7
Extreme 3.7
12.5
1 year 3.7
Extreme 3.7
12.5
3 years 1.06
Extreme 1.0625
12.5
5 years 1.06
Extreme 1.0625
52
10 years 1.06
Extreme 1.0625
202
Manager TitleAgeSince
Chief Executive Officer 64 2024-07-23
Director of Finance/CFO 50 2026-08-31
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 68 2016-01-31
Chairman 70 2020-06-17
Director/Board Member 59 2020-06-25
Date Insider Type Main position Quantity % Market Cap. Importance
10/14/25 Free

Chief Executive Officer

1,547,262 0.1485%
2/13/25 Free

Chief Executive Officer

5,000,000 0.4800%
2/13/25 Buy

Chief Executive Officer

575,000 0.0552%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-1.80%-21.58%-7.63% 77.59M
+0.50%+0.36%+55.89%+129.96% 1,143B
+0.86%+4.50%+42.43%+86.15% 647B
-0.14%-1.07%+25.42%+105.85% 506B
-0.05%+2.28%+49.14%+67.74% 384B
-0.63%-4.97%+60.15%+37.06% 350B
+0.34%+2.15%+25.26%+54.27% 293B
-0.45%+1.16%+1.74%+26.08% 265B
+0.87%+2.94%+55.18%+72.74% 242B
+0.08%+1.72%+32.15%+107.78% 197B
Average +0.29%+0.58%+32.58%+68.00% 402.76B
Weighted average by Cap. +0.46%+0.71%+42.63%+89.01%

Financials

2026 *2027 *
Net sales 53.48M 71.26M 63.86M 59M 99.67M 6.78B 101M 705M 281M 3.55B 267M 262M 11.24B 69.92M 93.16M 83.48M 77.13M 130M 8.87B 132M 922M 368M 4.64B 349M 342M 14.7B
Net income 258K 344K 308K 285K 481K 32.72M 487K 3.4M 1.36M 17.12M 1.29M 1.26M 54.24M 7.74M 10.32M 9.25M 8.54M 14.43M 982M 14.63M 102M 40.7M 514M 38.66M 37.89M 1.63B
Net Debt 18.45M 24.59M 22.03M 20.36M 34.39M 2.34B 34.87M 243M 96.99M 1.22B 92.12M 90.29M 3.88B 18M 23.98M 21.49M 19.85M 33.54M 2.28B 34.01M 237M 94.6M 1.19B 89.85M 88.06M 3.78B
Projected Income Statement - Annual - Shield Therapeutics plc
Logo Shield Therapeutics plc
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Employees
61
Date Price Change Volume
26-10-28 GBX 5.450 0.00% 48,465
26-10-27 GBX 5.450 -0.91% 545,025
26-10-26 GBX 5.500 0.00% 715,716
26-10-23 GBX 5.500 -1.79% 1,062,274
26-10-22 GBX 5.600 -1.75% 1,216,632
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Shield Therapeutics plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0545GBP
Average target price
0.1667GBP
Spread / Average Target
+205.82%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Shield Therapeutics plc